BioNTech SE (BioNTech SE) Interest Expense

: $-38 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioNTech SE's interest expense for the three months ended in Dec. 2023 was $ -4 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-38 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioNTech SE's Operating Income for the three months ended in Dec. 2023 was $ 652 Mil. BioNTech SE's Interest Expense for the three months ended in Dec. 2023 was $ -4 Mil. BioNTech SE's Interest Coverage for the quarter that ended in Dec. 2023 was 175.87. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioNTech SE Interest Expense Historical Data

The historical data trend for BioNTech SE's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-1.89

-2.43

-6.10

-17.16

-8.62

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense																0.64	-31.05	-1.41	-2.13	-3.71

BioNTech SE Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38 Mil.

BioNTech SE (NAS:BNTX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioNTech SE's Interest Expense for the three months ended in Dec. 2023 was $-4 Mil. Its Operating Income for the three months ended in Dec. 2023 was $652 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $208 Mil.

BioNTech SE's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	652.126	/	-3.708
	=	175.87

The higher the ratio, the stronger the company's financial strength is.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.